The massive settlement concerned kickbacks involving the United States’ biggest nursing home pharmacy, Omnicare and generic drug maker IVAX Pharmaceuticals and is just a part of a larger probe into potential Medicaid fraud by Big Pharma, said Business Week. Some feel the investigation focuses on industry paying consumer drug providers for special treatment, according to Business Week. The profits are believed to compromise patient care and increase costs.

The settlement that involves Omnicare and IVAX, a Teva Pharmaceutical Industries subsidiary, might drive criticism of the recent Obama Administration deal with Big Pharma hoped to help with health care reform, said Business Week. Opposing democrats feel larger cost savings should have been sought, Business Week added.

Omnicare will pay $98 million—and interest—to the federal government and some state Medicaid programs; IVAX will pay $14 million and interest. The agreement will settle claims that Omnicare, with IVAX, J&J, and two nursing home chains, were involved in kickbacks, said Business Week. The “Corporate Integrity Agreements” involve no admission of wrongdoing and include training and revised policies, reported Business Week.

The J&J probe continues, said Business Week. We wrote earlier this year that J&J was accused of defrauding Medicare and other federal health programs and that drug makers collected hundreds of millions of dollars in reimbursements for unapproved uses of the cardiac medication, Natrecor. According to J&J, it acknowledged receipt of a subpoena in 2005 in which the government sought paperwork on eight medications sold to Omnicare, said Business Week.

Taxpayers Against Fraud spokesman Patrick Burns, said the Justice Department is swamped with such fraud cases and drug manufacturers sell many similar medications; kickbacks are offer “a market edge,” reported Business Week. "In the pharmaceutical industry, the business isn't selling the best drug, it's the best scheme of kickbacks to the prescriber. Omnicare is just one of their sales points," quoted Business Week. "Patients have a right to depend on the integrity of the medical advice they're getting," said Tony West, assistant attorney general in the  civil division at the Justice Department. "When kickbacks are involved, the medical judgment of the provider is corrupted," added West, quoted Business Week.

Omnicare has a long history of alleged fraud and civil fraud complaint settlements that include, for example, said Business Week, receiving $8 million in payments from IVAX (2000-04) to purchase $50 million in generic medications and recommending doctors prescribe the drugs to their nursing home patients; of accepting J&J payments (1999 to 2004) to forcefully urge the prescription of anti-psychotic, Risperdal, while discouraging other medications; purportedly paying $50 million to Mariner Health Care and SavaSeniorCare (2004) to continue to refer Medicaid and Medicare patients to for drug services; and allegedly offering nursing home discounts on drug consultations (2005-8) in exchange for more costly services. Omnicare paid $102 million (2006) to settle Medicaid fraud cases in 43 states, and was required to enter a five-year corporate integrity agreement, Business Week added.

Last December’s government filing named Omnicare and other key drug makers, said Business Week, and alleges that for a period of some eight years, executives at Omnicare pushed drug staffers to switch brand-name drugs in nursing homes for rebates, regardless of prescriptions written for other medications, without advising doctors of the switches, and by providing “misleading information” drug costs and benefits.

David Henry, from the Institute for Clinical Evaluative Sciences in Toronto, Canada, and colleagues, looked at information released by Medicines Australia, which is that country’s “pharmaceutical industry representative body,” said Science Daily. Since 2007, Medicines Australia has been mandated to report information from “industry-sponsored function and educational event for health professionals,” explained Science Daily. The information must also include the event’s venue, cost, attendees, and “hospitality” provided, but does not require disclosure regarding speaker names, finances transacted between industry and speakers, and the companies’ part in selecting a speaker, noted Science Daily.

According to the research, said Science Daily, during 2007 in Australia, there were approximately 600 industry-sponsored events each week, with more than one-third taking place in “restaurants, hotels, or function centres” and hospitality, which includes refreshments and accommodations costing $17 million of the $31 million (Australian dollars) spent on such functions. The research also revealed that the sub-specialties most frequently hosted were oncologists (17.8 percent) and psychiatrists (15.2 percent), with family practice physicians at one-third and nurses at one-quarter of all events, reported Science Daily. The two sub-specialties cost more per person than other groups.

The researchers concluded that reporting standards do not allow sufficient transparency nor do the standards permit sufficient “assessment of the educational content” of these events, an issue since physicians can receive continuing medical education points, said Science Daily. The team recommends the topic and speakers be released.

In the United States, the relationships and finances exchanged between Industry and researchers have long been making the news and point to a bias in which patients are often not the prime concern.

Conflicts of interests can result in fines, fund freezes, and future grant loss, said the Atlanta Journal-Constitution in an earlier report. To help ensure no conflict-of-interest opportunities present themselves, the U.S. government mandates all such conflicts be reported by clinical researchers responsible for reviewing medications in advance of drug companies applying for U.S. Food and Drug Administration (FDA) approval. But, earlier this year, the Inspector General’s Office said the FDA has not proven itself reliable when it comes to finding drug research conflicts, a huge issue these days between medical professionals and industry.

Earlier this year, the Institute of Medicine recommended that researchers, medical school faculty, and private-practice doctors to forego gifts of any amount from medical companies and to decline to publish or present material ghostwritten or otherwise controlled by industry. Consulting arrangements should be limited to legitimate expert services spelled out in formal contracts and paid for at a fair market rate. Physicians should limit their interactions with company sales representatives and use free drug samples only for patients who cannot afford medications, the Institute said.

• Elemental and chemical testing revealed the presence of elemental sulfur in Chinese but not in non-Chinese drywall, and it also shows higher concentrations of strontium in Chinese drywall than in non-Chinese drywall. Testing conducted over the summer by federal and state agency radiation laboratories found no radiation safety risk to families in homes built with manufactured drywall. According to the press statement, the strontium found in this drywall does not pose a radiological risk.
• Chamber studies conducted by nationally-respected Lawrence Berkeley National Laboratory (LBL) show that Chinese drywall emits volatile sulfur compounds at a higher rate than the U.S. made drywall. More tests and analyses are underway at LBL to determine the specific chemical compounds that are being emitted, the CPSC said.
• Indoor air studies of 10 homes in Florida and Louisiana found that sulfur gases were either not present or were present in only limited or occasional concentrations inside the homes, and only when outdoor levels of sulfur compounds in the air were elevated.  The indoor air study did lead to a preliminary finding of detectable concentrations of two known irritant compounds, called acetaldehyde and formaldehyde. These irritant compounds were detected in homes both with and without Chinese drywall, and at concentrations that could worsen conditions such as asthma in sensitive populations, when air conditioners were not working or turned off.

• Acute and Subacute Transient Peripheral Neuropathy
• AL Amyloidosis
• Chloracne
• Chronic Lymphocytic Leukemia
• Diabetes Mellitus (Type 2)
• Hodgkin's Disease
• Multiple Myeloma
• Non-Hodgkin's Lymphoma
• Porphyria Cutanea Tarda
• Prostate Cancer
• Respiratory Cancers, and
• Soft Tissue Sarcoma (other than Osteosarcoma, Chondrosarcoma, Kaposi's sarcoma, or Mesothelioma)

• 1980: Relocation of families in Niagara Falls, N.Y., affected by The Love Canal toxic waste dump after an emergency declaration. This incident created the EPA’s federal Superfund.
• 1983: Relocation of families in Times Beach, Mo., due to dioxin contamination. Funds were transferred from the Superfund to FEMA to help the residents.

• Providing relief on mortgage payments for homeowners trying to rehabilitate their homes at the same time they have had to move their families because of potential health threats from the drywall.
• Developing a standard for remediating homes and certifying them as being free from the drywall problems.
• Allowing homeowners to receive a tax break to offset their rehabilitation costs.
• Providing help to homeowners trying to deal with insurance companies over the cost of the home rehabilitation.

• Consumers have reported a "rotten egg" smell within their homes.
• Consumers have reported health concerns such as irritated and itchy eyes and skin, difficulty in breathing, persistent cough, bloody noses, runny noses, recurrent headaches, sinus infection, and asthma attacks.
• Consumers have reported blackened and corroded metal components in their homes and the frequent replacement of components in air conditioning units.